Massachusetts Ends GLP-1 Weight-Loss Coverage for 22,000 on July 1 as State Seeks $15 Million Savings
Updated
Updated · WBUR News · Jun 23
Massachusetts Ends GLP-1 Weight-Loss Coverage for 22,000 on July 1 as State Seeks $15 Million Savings
3 articles · Updated · WBUR News · Jun 23
Summary
July 1 will cut off MassHealth coverage of GLP-1 weight-loss drugs for at least 22,000 people, with the state’s Group Insurance Commission also dropping the benefit for public employees.
Up to $450 a month in out-of-pocket costs is pushing some low-income patients to seek extra jobs or tap savings after officials said the drugs’ prices made coverage unsustainable.
$15 million in annual savings drove the move, with Massachusetts citing looming federal budget pressure while keeping GLP-1 coverage for diabetes and certain other conditions.
Doctors and drugmakers say the rollback treats obesity differently from other chronic diseases and could reverse health gains, since many patients regain weight after stopping treatment.
13 states had Medicaid coverage for GLP-1 weight loss drugs at the start of 2026, but Massachusetts joins a broader pullback as insurers struggle with soaring spending.
Massachusetts is cutting weight-loss drug coverage. Can new federal programs offer residents a lifeline?
Will ending coverage for obesity drugs save money or create a costlier health crisis later?
Massachusetts to End MassHealth GLP-1 Coverage for Weight Loss in 2026: Budget Pressures, Patient Impact, and National Policy Implications
Overview
Massachusetts will end MassHealth coverage for GLP-1 medications used for weight loss starting July 1, 2026. This policy change means patients must pay the full cost of these prescriptions themselves. The decision is causing distress among MassHealth beneficiaries, as many rely on these drugs to manage their weight. For example, Emily Putur, a 37-year-old shop owner, shared her sadness about losing coverage and the challenge of paying out of pocket. The shift highlights the financial and emotional impact on individuals who depend on GLP-1 medications for their health.